Design Therapeutics Q1 net loss narrows, beats analyst estimates

Design Therapeutics

28/04/2026 21:09

Overview

US biotech firm's Q1 net loss narrowed, beating analyst expectations

Company ended Q1 with $222.8 mln in cash, expects runway into 2029

Outlook

Company expects to provide DT-216P2 frataxin data update in H2 2026

Result Drivers

PIPELINE ADVANCEMENT - Co said continued operational execution and progress in clinical programs, including ongoing RESTORE-FA trial dosing, drove Q1 results

R&D SPENDING - R&D expenses remained high as co advanced multiple clinical and preclinical programs

Company press release: ID:nGNX6vQ9C0

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
Beat
-$17.64 mln
-$19.63 mln (5 Analysts)
Q1 Basic EPS
-$0.29
Q1 Operating Expenses
$19.71 mln
Q1 Operating Income
-$19.71 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Design Therapeutics Inc is $14.50, about 13.2% above its April 27 closing price of $12.81

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)